Cizzle Biotechnology Holdings PLC (LSE:CIZ) — Market Cap & Net Worth
Market Cap & Net Worth: Cizzle Biotechnology Holdings PLC (CIZ)
Cizzle Biotechnology Holdings PLC (LSE:CIZ) has a market capitalization of $72.34K (GBX594.59 Million) as of September 23, 2026. Listed on the LSE stock exchange, this UK-based company holds position #31576 globally and #1164 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cizzle Biotechnology Holdings PLC's stock price GBX1.50 by its total outstanding shares 396391773 (396.39 Million). Also see total assets of Cizzle Biotechnology Holdings PLC for a full breakdown of the balance sheet.
Cizzle Biotechnology Holdings PLC Market Cap History: 2015 to 2026
Cizzle Biotechnology Holdings PLC's market capitalization history from 2015 to 2026. Data shows change from $31.29 Million to $72.34K (-45.52% CAGR). Also see cash efficiency ratio of Cizzle Biotechnology Holdings PLC for how efficiently the company converts equity into cash flow.
Cizzle Biotechnology Holdings PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cizzle Biotechnology Holdings PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Cizzle Biotechnology Holdings PLC stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
3.18x
Cizzle Biotechnology Holdings PLC's market cap is 3.18 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $31.29 Million | $6.90 Million | -$2.77 Million | 4.53x | N/A |
| 2016 | $20.61 Million | $5.32 Million | -$159.38 | 3.88x | N/A |
| 2017 | $11.41 Million | $4.55 Million | -$118.20 | 2.51x | N/A |
| 2018 | $235.60K | $74.00K | -$2.06 Million | 3.18x | N/A |
Competitor Companies of CIZ by Market Capitalization
Companies near Cizzle Biotechnology Holdings PLC in the global market cap rankings as of September 23, 2026. Review CIZ tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Cizzle Biotechnology Holdings PLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $129.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #336 globally with a market cap of $80.46 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $61.21 Billion USD ( AU$86.50 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #508 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $129.45 Billion | $510.72 |
| #336 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $80.46 Billion | $798.17 |
| #455 | CSL Ltd | AU:CSL | $61.21 Billion | AU$178.30 |
| #508 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $172.94 |
Cizzle Biotechnology Holdings PLC Historical Marketcap From 2015 to 2026
Between 2015 and today, Cizzle Biotechnology Holdings PLC's market cap moved from $31.29 Million to $ 72.34K, with a yearly change of -45.52%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX72.34K | -3.23% |
| 2025 | GBX74.76K | 0.00% |
| 2024 | GBX74.76K | -20.51% |
| 2023 | GBX94.05K | +34.48% |
| 2022 | GBX69.93K | -51.67% |
| 2021 | GBX144.69K | -73.91% |
| 2019 | GBX554.64K | +135.41% |
| 2018 | GBX235.60K | -97.94% |
| 2017 | GBX11.41 Million | -44.64% |
| 2016 | GBX20.61 Million | -34.12% |
| 2015 | GBX31.29 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 22nd, 2026 the market cap of Cizzle Biotechnology Holdings PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $72.34K USD |
| MoneyControl | $72.34K USD |
| MarketWatch | $72.34K USD |
| marketcap.company | $72.34K USD |
| Reuters | $72.34K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cizzle Biotechnology Holdings PLC
Cizzle Biotechnology Holdings Plc, together with its subsidiaries, operates as a cancer diagnostics company in the United Kingdom. It develops a non-invasive blood test for early lung cancer detection using CIZ1B biomarker technology. The company was formerly known as Cizzle Biotechnology Limited and changed its name to Cizzle Biotechnology Holdings Plc in May 2021. Cizzle Biotechnology Holdings … Read more